세계의 여성 불임 시장 보고서(2025년)

Female Infertility Global Market Report 2025

US $ 4,490 ￦ 6,265,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,056,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,846,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

여성 불임 시장 규모는 향후 몇 년 동안 안정적인 성장을 보일 것으로 예상되며, 2029년에는 4.1%의 연평균 복합 성장률(CAGR)로 21억 9,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 불임 문제에 대한 인식 증가, 다낭성 난소 증후군 사례 증가, 자궁 이상 증가, 유전성 질환 발생률 증가, 비만 증가 등 여러 요인에 기인하는 것으로 추정됩니다. 이 기간에 예상되는 주요 동향으로는 착상 전 유전자 검사의 발전, 기술 혁신, 신규 진단 기술, 가임력 보존 기술, 원격 의료의 부상 등을 꼽을 수 있습니다.

불임의 유병률 증가는 향후 몇 년 동안 여성 불임 시장의 확대를 촉진할 것으로 예측됩니다. 불임은 피임 없이 12개월 동안 정기적으로 성관계를 가졌음에도 불구하고 임신이 되지 않는 상태를 말합니다. 불임 증가는 출산 지연, 생활습관 변화, 환경 독소, 비만율 증가, 스트레스 수준 증가 등의 요인에 의해 영향을 받고 있습니다. 여성 불임 치료는 불임을 방해하는 근본적인 의학적, 호르몬 또는 구조적 문제를 해결하고 관리하여 임신 가능성을 높이고 영구적인 불임을 예방하기 위해 필요합니다. 예를 들어, 2024년 7월 영국의 공공 기관인 Human Fertilization and Embryology Authority(영국 보건사회부 산하)는 영국의 허가된 불임 치료 클리닉이 2022년에 5,500명의 환자에게 약 77,000회의 신선배아 이식 및 동결배아 이식 체외수정을 실시했다고 보고했습니다. 이들 환자의 90% 이상이 파트너와 함께 치료를 받고 있으며, 약 10만 명이 참여하고 있습니다. 그 결과, 불임 유병률 증가가 여성 불임 시장의 성장을 주도하고 있습니다.

여성 불임 시장의 주요 기업들은 경쟁 우위를 확보하기 위해 비침습적 진단 검사와 같은 혁신적인 제품 개발에 주력하고 있습니다. 비침습적 진단 검사는 수술이나 신체에 침투하지 않고 상태나 질병을 감지하는 의료 검사입니다. 예를 들어, 미국에 본사를 둔 생명공학 기업 헤라노바 생명과학(Heranova Lifesciences)는 2024년 8월 자궁내막증 비침습적 진단 검사 '허리졸브(HerResolve)'의 얼리 액세스 프로그램을 도입했습니다. 자궁내막증은 전 세계 약 2억 명의 여성이 앓고 있는 질환으로 불임, 통증, 출혈 등의 증상을 유발합니다. 많은 여성들이 증상 발현 후 정확한 진단을 받기까지 평균 7-10년이 걸립니다. HerResolve는 이러한 진단 지연을 몇 년에서 몇 개월로 단축하여 환자 및 의료 결과를 개선할 수 있는 잠재력을 가지고 있습니다.의 목표는 이 타임라인을 크게 단축하고 환자 치료와 결과를 개선하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 여성 불임 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 여성 불임 시장 : 성장률 분석
• 세계의 여성 불임 시장 실적 : 규모와 성장, 2019-2024
• 세계의 여성 불임 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 여성 불임 전체 시장(TAM)

제6장 시장 세분화

• 세계의 여성 불임 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Clomiphene Citrate
• Gonadotropins
• Metformin
• Letrozole
• Bromocriptine
• 세계의 여성 불임 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 비경구
• 기타 투여 경로
• 세계의 여성 불임 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 여성 불임 시장 : Clomiphene Citrate별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 주사용
• 세계의 여성 불임 시장 : Gonadotropins별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 재조합 성선 ㅏ극 호르몬
• 비뇨기 성선 자극 호르몬
• 인간 융모 성선 자극 호르몬(hCG)
• 세계의 여성 불임 시장 : Metformin별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 즉시 방출 메트포르민
• 장기 방출 메트포르민
• 세계의 여성 불임 시장 : Letrozole별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구용 레트로졸 정제
• 주사제 레트로졸
• 세계의 여성 불임 시장 : Bromocriptine별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구 브로모크립틴 정제
• 비강내 브로모크립틴

제7장 지역별/국가별 분석

• 세계의 여성 불임 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 여성 불임 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 여성 불임 시장 : 경쟁 구도
• 여성 불임 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• AstraZeneca Plc
• Abbott Laboratories
• Mayo Clinic
• Teva Pharmaceutical Industries Ltd
• Commonwealth Serum Laboratories Ltd
• Organon Theramex
• Juniper Reproductive Health Ltd.
• Sumitomo Pharma
• Ferring Pharmaceuticals
• Livzon Pharmaceutical Group Co.
• Mankind Pharma
• Kissei Pharmaceutical Co Ltd
• ASKA Pharmaceutical Co. Ltd.
• Fuji Pharma Co. Ltd.
• ARMC IVF

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 여성 불임 시장(2029년) : 새로운 기회를 제공하는 국가
• 여성 불임 시장(2029년) : 새로운 기회를 제공하는 부문
• 여성 불임 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to sustain a pregnancy. It is a multifactorial condition that results from various factors affecting the reproductive system.

The main treatments for female infertility include clomiphene citrate, gonadotropins, metformin, letrozole, and bromocriptine. Clomiphene citrate is commonly prescribed to stimulate ovulation in women with infertility. It can be administered in various forms, such as oral, parenteral, and others, and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The female infertility market research report is one of a series of new reports from The Business Research Company that provides female infertility market statistics, including female infertility industry global market size, regional shares, competitors with a female infertility market share, detailed female infertility market segments, market trends and opportunities, and any further data you may need to thrive in the female infertility industry. This female infertility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The female infertility market size has grown steadily in recent years. It will grow from $1.79 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth during the historic period can be attributed to several factors, including the growing trend of women delaying childbirth, changes in lifestyle, increased government initiatives, a rising aging population, and the growing use of assisted reproductive technology (ART) treatments.

The female infertility market size is expected to see steady growth in the next few years. It will grow to $2.19 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth during the forecast period can be attributed to several factors, including rising awareness of fertility issues, an increase in cases of polycystic ovary syndrome, a growing number of uterine abnormalities, a higher incidence of genetic disorders, and increasing obesity. Key trends expected during this period include advancements in preimplantation genetic testing, technological innovations, novel diagnostic technologies, fertility preservation techniques, and the rise of telemedicine.

The growing prevalence of infertility is expected to fuel the expansion of the female infertility market in the coming years. Infertility is defined as the inability to conceive after 12 months of regular, unprotected sexual intercourse. The rise in infertility is influenced by factors such as delayed childbearing, lifestyle changes, environmental toxins, increasing obesity rates, and higher stress levels. Treatment for female infertility is necessary to address and manage the underlying medical, hormonal, or structural issues that hinder fertility, improving the chances of conception and preventing permanent infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a UK-based public body under the Department of Health and Social Care, reported that licensed fertility clinics in the UK conducted nearly 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. More than 90% of these patients received treatment with a partner, involving around 100,000 individuals. As a result, the rising prevalence of infertility is driving the growth of the female infertility market.

Key companies in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive advantage. A non-invasive diagnostic test is a medical examination that detects conditions or diseases without the need for surgery or penetration of the body. For example, in August 2024, Heranova Lifesciences, a biotech company based in the US, introduced an early access program for HerResolve, a non-invasive diagnostic test designed for endometriosis. Endometriosis affects around 200 million women globally, causing symptoms such as infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7 to 10 years from the onset of symptoms, largely due to the diverse nature of symptoms and the invasive procedure required for the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve has the potential to reduce this diagnostic delay from years to months, improving patient and healthcare outcomes. The goal of HerResolve is to significantly shorten this timeline, enhancing patient care and results.

In April 2023, CCRM Fertility, a network of fertility clinics based in the US, acquired the New Hope Center for Reproductive Medicine for an undisclosed amount. This acquisition allows CCRM to expand its fertility services on the East Coast, providing greater access to high-quality fertility care, advanced testing, state-of-the-art laboratories, and in-house genetics and research, all contributing to leading success rates. The New Hope Center for Reproductive Medicine, also based in the US, is a fertility clinic offering a variety of services, including in vitro fertilization (IVF) to address female infertility.

Major players in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd.

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in female infertility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the female infertility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The female infertility market consists of revenues earned by entities by providing services such as hormonal therapy and treatment, genetic testing and counseling, ovulation induction, egg and sperm donation and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. The female infertility market also includes sales of fertility drugs, ovulation test kits, fertility supplements, insemination devices and ultrasound machines for fertility monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Female Infertility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on female infertility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for female infertility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The female infertility market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Clomiphene Citrate; Gonadotropins; Metformin; Letrozole; Bromocriptine
• 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 3) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Clomiphene Citrate: Oral Clomiphene Citrate; Injectable Clomiphene Citrate
• 2) By Gonadotropins: Recombinant Gonadotropins; Urinary Gonadotropins; Human Chorionic Gonadotropin (hCG)
• 3) By Metformin: Immediate-Release Metformin; Extended-Release Metformin
• 4) By Letrozole: Oral Letrozole Tablets; Injectable Letrozole
• 5) By Bromocriptine: Oral Bromocriptine Tablets; Intranasal Bromocriptine
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck And Co. Inc; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Female Infertility Market Characteristics

3. Female Infertility Market Trends And Strategies

4. Female Infertility Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Female Infertility Growth Analysis And Strategic Analysis Framework

• 5.1. Global Female Infertility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Female Infertility Market Growth Rate Analysis
• 5.4. Global Female Infertility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Female Infertility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Female Infertility Total Addressable Market (TAM)

6. Female Infertility Market Segmentation

• 6.1. Global Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clomiphene Citrate
• Gonadotropins
• Metformin
• Letrozole
• Bromocriptine
• 6.2. Global Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.3. Global Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Female Infertility Market, Sub-Segmentation Of Clomiphene Citrate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Clomiphene Citrate
• Injectable Clomiphene Citrate
• 6.5. Global Female Infertility Market, Sub-Segmentation Of Gonadotropins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Gonadotropins
• Urinary Gonadotropins
• Human Chorionic Gonadotropin (hCG)
• 6.6. Global Female Infertility Market, Sub-Segmentation Of Metformin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Metformin
• Extended-Release Metformin
• 6.7. Global Female Infertility Market, Sub-Segmentation Of Letrozole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Letrozole Tablets
• Injectable Letrozole
• 6.8. Global Female Infertility Market, Sub-Segmentation Of Bromocriptine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Bromocriptine Tablets
• Intranasal Bromocriptine

7. Female Infertility Market Regional And Country Analysis

• 7.1. Global Female Infertility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Female Infertility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Female Infertility Market

• 8.1. Asia-Pacific Female Infertility Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Female Infertility Market

• 9.1. China Female Infertility Market Overview
• 9.2. China Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Female Infertility Market

• 10.1. India Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Female Infertility Market

• 11.1. Japan Female Infertility Market Overview
• 11.2. Japan Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Female Infertility Market

• 12.1. Australia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Female Infertility Market

• 13.1. Indonesia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Female Infertility Market

• 14.1. South Korea Female Infertility Market Overview
• 14.2. South Korea Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Female Infertility Market

• 15.1. Western Europe Female Infertility Market Overview
• 15.2. Western Europe Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Female Infertility Market

• 16.1. UK Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Female Infertility Market

• 17.1. Germany Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Female Infertility Market

• 18.1. France Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Female Infertility Market

• 19.1. Italy Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Female Infertility Market

• 20.1. Spain Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Female Infertility Market

• 21.1. Eastern Europe Female Infertility Market Overview
• 21.2. Eastern Europe Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Female Infertility Market

• 22.1. Russia Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Female Infertility Market

• 23.1. North America Female Infertility Market Overview
• 23.2. North America Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Female Infertility Market

• 24.1. USA Female Infertility Market Overview
• 24.2. USA Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Female Infertility Market

• 25.1. Canada Female Infertility Market Overview
• 25.2. Canada Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Female Infertility Market

• 26.1. South America Female Infertility Market Overview
• 26.2. South America Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Female Infertility Market

• 27.1. Brazil Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Female Infertility Market

• 28.1. Middle East Female Infertility Market Overview
• 28.2. Middle East Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Female Infertility Market

• 29.1. Africa Female Infertility Market Overview
• 29.2. Africa Female Infertility Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Female Infertility Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Female Infertility Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Female Infertility Market Competitive Landscape And Company Profiles

• 30.1. Female Infertility Market Competitive Landscape
• 30.2. Female Infertility Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Female Infertility Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Abbott Laboratories
• 31.3. Mayo Clinic
• 31.4. Teva Pharmaceutical Industries Ltd
• 31.5. Commonwealth Serum Laboratories Ltd
• 31.6. Organon Theramex
• 31.7. Juniper Reproductive Health Ltd.
• 31.8. Sumitomo Pharma
• 31.9. Ferring Pharmaceuticals
• 31.10. Livzon Pharmaceutical Group Co.
• 31.11. Mankind Pharma
• 31.12. Kissei Pharmaceutical Co Ltd
• 31.13. ASKA Pharmaceutical Co. Ltd.
• 31.14. Fuji Pharma Co. Ltd.
• 31.15. ARMC IVF

32. Global Female Infertility Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Female Infertility Market

34. Recent Developments In The Female Infertility Market

35. Female Infertility Market High Potential Countries, Segments and Strategies

• 35.1 Female Infertility Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Female Infertility Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Female Infertility Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료